KHC
20
2
STX
55
-2
TEL
66
-3
SLB
53
-3
DOV
69
2
WHR
65
-7
EW
46
3
SPG
63
7
COST
66
3
ISRG
74
3
NKE
39
-3
FMC
37
-2
HCP
62
-8
LUV
42
-3
RIG
55
-6
PNW
70
3
SIG
50
-5
KO
47
-2
LLY
53
6
UAL
83
-2
KHC
20
2
STX
55
-2
TEL
66
-3
SLB
53
-3
DOV
69
2
WHR
65
-7
EW
46
3
SPG
63
7
COST
66
3
ISRG
74
3
NKE
39
-3
FMC
37
-2
HCP
62
-8
LUV
42
-3
RIG
55
-6
PNW
70
3
SIG
50
-5
KO
47
-2
LLY
53
6
UAL
83
-2
Financhill
Back

Black Diamond Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
27

BDTX
Black Diamond Therapeutics

Last Price:
2.57
Seasonality Move:
28.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Black Diamond Therapeutics Price Quote

$2.57
+0.10 (+4.05%)
(Updated: November 27, 2024 at 5:55 PM ET)

Black Diamond Therapeutics Key Stats

Sell
27
Black Diamond Therapeutics (BDTX) is a Sell
Day range:
$2.41 - $2.58
52-week range:
$2.16 - $7.66
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.43%
Volume:
401.4K
Avg. volume:
577K
1-year change:
9.29%
Market cap:
$139.8M
Revenue:
$0
EPS:
$-1.33

How Much Does Black Diamond Therapeutics Make?

Data Unavailable

Is Black Diamond Therapeutics Growing As A Company?

Data Unavailable

Black Diamond Therapeutics Stock Price Performance

What Is Black Diamond Therapeutics 52-Week High & Low?

Black Diamond Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Black Diamond Therapeutics?

Is Black Diamond Therapeutics Cash Flow Positive?

  • What Is BDTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$61.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $25.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $1.4M

Black Diamond Therapeutics Return On Invested Capital

Data Unavailable

Black Diamond Therapeutics Earnings Date & Stock Price

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics Dividend Yield

Black Diamond Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 21.5%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 14.50
Upside from Last Price: 487.04%

Major Shareholders

  • How many BDTX shares are owned by institutional investors?
    96.1M BDTX shares are owned by institutional investors
  • How many BDTX shares are owned by insiders?
    1.2M BDTX shares are owned by insiders